Case Study: The UII Tango and Mr..
Case Study: The UII Tango and Mr. Khan’s Appetite Blues Patient: Mr. Khan, a 58-year-old male residing in Lahore, Pakistan, presented with a two-year history.
Read MoreUrotensin II – A New Player in.
Urotensin II – A New Player in the Thyroid Storm: Unraveling its Role in Hyperthyroidism Abstract: Thyroid storm, a rare and life-threatening complication of hyperthyroidism,.
Read MoreCase Study: Urotensin II’s Unmasking in a.
Case Study: Urotensin II’s Unmasking in a Thyroid Storm Patient: Sarah, a 35-year-old woman with Graves’ disease diagnosed two years ago. Despite antithyroid medication adherence,.
Read MoreBeyond Diabetes: Urotensin II and the Complexities.
Beyond Diabetes: Urotensin II and the Complexities of Polycystic Ovary Syndrome (PCOS) Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrine disorder affecting approximately 1 in.
Read MoreA Double-Edged Sword: Urotensin II in the.
A Double-Edged Sword: Urotensin II in the Paradox of Addison’s Disease In the labyrinthine realm of human physiology, few conditions present such a captivating paradox.
Read MoreCase Study: Urotensin II and Personalized Medicine.
Case Study: Urotensin II and Personalized Medicine in PCOS Management Patient: Sarah, a 28-year-old woman, presented with symptoms of irregular menstrual cycles, hirsutism, and acne.
Read MoreCase Study: Unveiling the Urotensin II Paradox.
Case Study: Unveiling the Urotensin II Paradox in Sarah’s Addison’s Disease Patient: Sarah, a 35-year-old woman, diagnosed with Addison’s disease two years ago. Presenting Symptoms:.
Read MoreFrom Bench to Bedside: Targeting Urotensin II.
From Bench to Bedside: Targeting Urotensin II for Novel Hyperprolactinemia Therapies Hyperprolactinemia, a condition characterized by elevated prolactin levels in the blood, is a complex.
Read MoreCase Study: Urotensin II and Hyperprolactinemia –.
Case Study: Urotensin II and Hyperprolactinemia – A Tale of Two Patients Introduction: Hyperprolactinemia, characterized by elevated prolactin levels, presents diverse challenges for clinicians. While.
Read MoreUnveiling the VIP: Vasoactive Intestinal Peptide’s Intriguing.
Unveiling the VIP: Vasoactive Intestinal Peptide’s Intriguing Role in Graves’ Disease Immunopathology Delving deeper into the intricate world of VIP’s involvement in Graves’ disease: Mechanisms.
Read More- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268